Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Gallbladder Cancer
- PDF / 960,446 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 102 Downloads / 183 Views
CLINICAL INVESTIGATION
INTERVENTIONAL ONCOLOGY
Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Gallbladder Cancer Kanglian Zheng1 • Xiaodong Wang1 • Guang Cao1 • Liang Xu1 • Xu Zhu1 Liqiang Fu2 • Shijie Fu1 • Haihui Cheng1 • Renjie Yang1
•
Received: 16 May 2020 / Accepted: 18 September 2020 Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2020
Abstract Purpose The aim of this study was to assess the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin and 5-fluorouracil for patients with advanced gallbladder cancer (GBC). Materials and Methods Twenty-six patients with advanced GBC, who underwent HAIC with oxaliplatin and 5-fluorouracil from January 2012 to July 2019, were enrolled in this retrospective study. The HAIC regimen consisted of infusions of oxaliplatin at 40 mg/m2 for 2 h, followed by 5-fluorouracil at 800 mg/m2 for 22 h on days 1–3 every 3–4 weeks. A maximum of six cycles of HAIC were applied for tumor control patients followed by maintenance with oral capecitabine or S-1. Overall survival (OS), progression-free survival (PFS), tumor response, and adverse events were investigated. Results Six of the 26 patients (23.1%) had failed systemic chemotherapy, 8/26 (30.8%) patients had failed various local therapies, and 9/26 (34.6%) patients had contraindications to systemic chemotherapy. The median OS was 13.5 months, and the median PFS was 10.0 months. The overall response rate was 69.2% (18/26), and disease control rate was 92.3% (24/26). Carcinoembryonic antigen & Xiaodong Wang [email protected] 1
Department of Interventional Therapy, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), 52 Fucheng Road, Haidian District, Beijing, China
2
Department of Biostatistics, School of Public Health, Southern Medical University, 1838 Guangzhou Avenue North, Baiyun District, Guangzhou, China
(CEA) C 10 U/ml (p = 0.003) and carbohydrate antigen 19–9 (CA19-9) C 200 U/ml (p = 0.000) were independent risk factors for decreased survival. The most frequent Grade 3 or 4 treatment-related adverse event was liver dysfunction (4, 15.4%). Conclusion HAIC with oxaliplatin and 5-fluorouracil is an acceptable and well-tolerated treatment for advanced gallbladder cancer even for patients in whom systemic chemotherapy had failed or is contraindicated. Level of Evidence Level 2, Observation Study with Dramatic Effect Keywords Hepatic arterial infusion chemotherapy Advanced gallbladder cancer Oxaliplatin 5-Fluorouracil Abbreviations GBC Gallbladder cancer HAIC Hepatic arterial infusion chemotherapy TACE Trans-arterial chemoembolization TARE Trans-arterial radioembolization OS Overall survival PFS Progression-free survival CEA Carcinoembryonic antigen CA 19-9 Carbohydrate antigen 19-9 TBIL Total bilirubin GDA Gastroduodenal artery
123
K Zheng et al.: Hepatic Arterial Inf
Data Loading...
